BR112022000925A2 - Nanopartículas de rna multilamelares - Google Patents

Nanopartículas de rna multilamelares

Info

Publication number
BR112022000925A2
BR112022000925A2 BR112022000925A BR112022000925A BR112022000925A2 BR 112022000925 A2 BR112022000925 A2 BR 112022000925A2 BR 112022000925 A BR112022000925 A BR 112022000925A BR 112022000925 A BR112022000925 A BR 112022000925A BR 112022000925 A2 BR112022000925 A2 BR 112022000925A2
Authority
BR
Brazil
Prior art keywords
methods
nanoparticles
subject
multilamellar
nucleic acid
Prior art date
Application number
BR112022000925A
Other languages
English (en)
Inventor
Carlos Rinaldi
Duane Mitchell
Elias Sayour
Ruben Mendez-Gomez Hector
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of BR112022000925A2 publication Critical patent/BR112022000925A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

nanopartículas de rna multilamelares. a presente invenção refere-se a nanopartícula que compreende uma superfície carregada positivamente e um interior que compreende (i) um núcleo e (ii) pelo menos duas camadas de ácido nucleico, em que cada camada de ácido nucleico está posicionada entre uma bicamada lipídica catiônica. métodos para fazer tais nanopartículas são ainda fornecidos no presente documento. adicionalmente, são fornecidas células, populações de células e composições farmacêuticas que compreendem as nanopartículas presentemente descritas. além disso, são fornecidos métodos para aumentar uma resposta imune contra um tumor em um indivíduo, métodos para distribuir moléculas de rna a um microambiente intratumoral, linfonodo e/ou um órgão reticuloendotelial em um indivíduo e métodos para tratar um indivíduo com uma doença.
BR112022000925A 2019-07-19 2020-07-17 Nanopartículas de rna multilamelares BR112022000925A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876440P 2019-07-19 2019-07-19
US201962877598P 2019-07-23 2019-07-23
US201962884983P 2019-08-09 2019-08-09
US201962933326P 2019-11-08 2019-11-08
PCT/US2020/042606 WO2021016106A1 (en) 2019-07-19 2020-07-17 Multilamellar rna nanoparticles

Publications (1)

Publication Number Publication Date
BR112022000925A2 true BR112022000925A2 (pt) 2022-05-17

Family

ID=74193752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000925A BR112022000925A2 (pt) 2019-07-19 2020-07-17 Nanopartículas de rna multilamelares

Country Status (8)

Country Link
US (1) US20220287969A1 (pt)
EP (1) EP3999034A4 (pt)
JP (1) JP2022541586A (pt)
KR (1) KR20220035434A (pt)
AU (1) AU2020316335A1 (pt)
BR (1) BR112022000925A2 (pt)
CA (1) CA3144388A1 (pt)
WO (1) WO2021016106A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168290A1 (en) * 2020-02-19 2021-08-26 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
WO2021202772A1 (en) * 2020-04-01 2021-10-07 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
EP4333811A1 (en) * 2021-05-07 2024-03-13 University of Florida Research Foundation, Inc. Car t cell therapy method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112597A1 (en) * 2010-03-08 2011-09-15 Northeastern University Magnetic nanoplatforms for theranostic and multi-modal imaging applications
KR102128248B1 (ko) * 2011-06-08 2020-07-01 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
EP3790533A1 (en) * 2018-05-08 2021-03-17 University of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
WO2020037102A1 (en) * 2018-08-15 2020-02-20 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors

Also Published As

Publication number Publication date
AU2020316335A1 (en) 2022-02-17
EP3999034A4 (en) 2023-08-23
WO2021016106A1 (en) 2021-01-28
US20220287969A1 (en) 2022-09-15
CA3144388A1 (en) 2021-01-28
EP3999034A1 (en) 2022-05-25
JP2022541586A (ja) 2022-09-26
KR20220035434A (ko) 2022-03-22
WO2021016106A8 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
BR112022000925A2 (pt) Nanopartículas de rna multilamelares
Hadla et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models
Conlan et al. Exosomes as reconfigurable therapeutic systems
Liu et al. MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
Hattinger et al. Drug resistance in osteosarcoma: emerging biomarkers, therapeutic targets and treatment strategies
Greco et al. PLK-1 silencing in bladder cancer by siRNA delivered with exosomes
Shu et al. Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology
Chen et al. Mastering dendrimer self‐assembly for efficient siRNA delivery: from conceptual design to in vivo efficient gene silencing
Hattori et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex
Tomuleasa et al. Nanopharmacology in translational hematology and oncology
MX2021005389A (es) Formulaciones de nanoparticulas lipidicas.
Wang et al. Isothermal self-assembly of spermidine–DNA nanostructure complex as a functional platform for cancer therapy
Sun et al. Anti-miRNA oligonucleotide therapy for chondrosarcoma
Zhao et al. Cancer cell membrane camouflaged mesoporous silica nanoparticles combined with immune checkpoint blockade for regulating tumor microenvironment and enhancing antitumor therapy
Awasthi et al. Therapeutic prospects of microRNAs in cancer treatment through nanotechnology
Mirzaei et al. Pre-clinical and clinical applications of small interfering RNAs (siRNA) and co-delivery systems for pancreatic cancer therapy
BR112016023004A2 (pt) sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma
Ye et al. A novel targeted therapy system for cervical cancer: co-delivery system of antisense LncRNA of MDC1 and oxaliplatin magnetic thermosensitive cationic liposome drug carrier
Delehedde et al. Intracellular routing and recognition of lipid-based mRNA nanoparticles
Liu et al. Arrayed rGOSH/PMASH microcapsule platform integrating surface topography, chemical cues, and electrical stimulation for three‐dimensional neuron‐like cell growth and neurite sprouting
Ma et al. Cancer cell targeting, controlled drug release and intracellular fate of biomimetic membrane-encapsulated drug-loaded nano-graphene oxide nanohybrids
Singh et al. RNA interference nanotherapeutics for treatment of glioblastoma multiforme
Alamoudi et al. Thermoresponsive pegylated bubble liposome nanovectors for efficient siRNA delivery via endosomal escape
Fraga et al. Influence of phospholipid composition on cationic emulsions/DNA complexes: physicochemical properties, cytotoxicity, and transfection on Hep G2 cells
Mehta et al. Targeting respiratory diseases using miRNA inhibitor based nanotherapeutics: Current status and future perspectives

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]